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Abstract
Background: Postnatal endothelial progenitor cells (EPCs) have been successfully isolated from whole bone marrow, 
blood and the walls of conduit vessels. They can, therefore, be classified into circulating and resident progenitor cells. 
The differentiation capacity of resident lung endothelial progenitor cells from mouse has not been evaluated.
Results: In an attempt to isolate differentiated mature endothelial cells from mouse lung we found that the lung 
contains EPCs with a high vasculogenic capacity and capability of de novo vasculogenesis for blood and lymph vessels.
Mouse lung microvascular endothelial cells (MLMVECs) were isolated by selection of CD31+ cells. Whereas the majority
of the CD31+ cells did not divide, some scattered cells started to proliferate giving rise to large colonies (> 3000 cells/
colony). These highly dividing cells possess the capacity to integrate into various types of vessels including blood and
lymph vessels unveiling the existence of local microvascular endothelial progenitor cells (LMEPCs) in adult mouse lung.
EPCs could be amplified > passage 30 and still expressed panendothelial markers as well as the progenitor cell
antigens, but not antigens for immune cells and hematopoietic stem cells. A high percentage of these cells are also
positive for Lyve1, Prox1, podoplanin and VEGFR-3 indicating that a considerabe fraction of the cells are committed to
develop lymphatic endothelium. Clonogenic highly proliferating cells from limiting dilution assays were also bipotent.
Combined in vitro and in vivo spheroid and matrigel assays revealed that these EPCs exhibit vasculogenic capacity by
forming functional blood and lymph vessels.
Conclusion: The lung contains large numbers of EPCs that display commitment for both types of vessels, suggesting 
that lung blood and lymphatic endothelial cells are derived from a single progenitor cell.
Background
In the developing embryo blood vessels and later also
lymphatic vessels are formed via an initial process of vas-
culogenesis. This is followed by sprouting and intussus-
ceptive growth of the vessels, termed angiogenesis for
blood vessels and lymphangiogenesis for lymph vessels.
These mechanisms give rise to a complete blood and
lymphvascular system consisting of arteries, veins, capil-
laries and collectors. Endothelial cells (ECs) are specified
according to the circulatory system (blood versus lymph)
and to the vessel type (vein, artery, capillary) to which
they belong [1]. However, ECs from diseased tissues can
have different molecular markers and characteristics
from those found in normal vascular beds [2,3]. The
interface formed by ECs between blood or lymph and the
surrounding tissue has different physiological functions
in different organs and is an important attribute for tissue
homeostasis. Although differentiated endothelium hardly
proliferates in most organs, under pathological condi-
tions and in female reproductive organs ECs are replaced
and proliferate to support tissue growth and to preserve
vascular and organ homeostasis [4,5]. Already in the
1970s, the presence of fast-growing endothelial cells
within niches of the vessel intima was postulated [6].
These early findings together with more recent data sug-
gest that the turnover rate of ECs in conduit blood vessels
in vivo is in the range of several years [4,7]. Heterogeneity
of endothelial cells does not only exist with regard to
blood and lymphatic vessels, but also along the arterial-
capillary-venule axis, and between capillaries of specific
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tissues and organs [4,5]. Physiological capillary growth
can achieve high rates, for example, cyclically capillary
growth is found in the corpus luteum to transport blood
to the granulosa cells during the menstrual cycle [8].
Thereby, the proliferation rate of ECs is comparable in its
extent to fast growing tumours [9]. Therefore, at least
some microvascular ECs and ECs in specific niches pos-
sess high endogenous proliferation capacities in vivo, as
well as high angiogenic potential as part of their physio-
logical role.
Under  in vitro conditions, both microvascular and
macrovascular ECs can reestablish their proliferative
phenotype but it has been shown that, for example, pul-
monary microvascular ECs from rats grow approximately
twice as fast as pulmonary artery ECs [10,11]. At the
molecular level, microvascular ECs possess higher
expression of cell cycle regulating genes and inactivation
of antimitogenic proteins [12]. Based on these results, it is
not clear whether all microvascular ECs exhibit a higher
proliferation rate or whether only a subpopulation of rep-
lication-competent cells, as suggested by Schwarz and
Benditt [6] from their in vivo findings, account for such
high proliferation rates.
More recently it has been demonstrated that prepara-
tions of human large vessel endothelial cells contain a
moderate number of cells that have a higher single-cell-
layer growth potential and show endothelial colony-
forming activity [13]. Thereby, it has been demonstrated
that ~50% of primary cells seeded as single cells grow, but
only ~12.5% of these cells displayed a high proliferative
behaviour. Based on their high capacity for self-renewal
and regeneration, fast proliferating endothelial colony-
forming cells were considered to be endothelial progeni-
tors (EPCs) [13-15]. Interestingly, these isolated EPCs
demonstrated an intrinsic vasculogenic capacity, as
shown by their capability to form de novo vessels in vivo,
the most striking function for the endothelium. Recently,
similar cells were found in rats where they were isolated
from the lung as resident EPCs [11]. A comprehensive list
of the different EPCs, their nomenclature, source and
surface markers can be found in a very recently published
review [16]. These results support earlier observations by
Schwartz and Benditt for the endothelium of the vessel
wall and prove that EC populations from conduit vessels
contain progenitor niches [6].
I n  r e c e n t  y e a r s ,  w e  h a v e  e s t a b l i s h e d  n u m e r o u s
endothelial cell lines from different mouse strains and
immortalized them by transduction with polyoma middle
T (PmT) virus [17]. However, immortalized ECs may lose
some of their typical characteristics, and we, therefore,
looked for a reliable source of replication-competent
mouse ECs. We finally used lung tissue for the isolation of
mouse microvascular endothelial cells and discovered
that lung tissue contains a large number of fast-growing
resident EPCs, with vasculogenic capacity in vitro and in
vivo, and capable of forming both blood and lymphatic
capillaries. This is the first report, which suggests that
blood and lymphatic endothelial cells in the lung are
derived from a common progenitor cell.
Results
Mouse lungs contain ECs with high proliferation capacity
Using adult mouse lung for magneto-bead selection of
CD31+ endothelial cells, we discovered that the lung con-
tains endothelial cells, which have a high proliferative
capacity. When lungs from three animals were combined
and used for tissue homogenisation followed by anti-
CD31 cell sorting, only very few isolated cells started to
proliferate (Figure 1a). Six days after cell isolation, indi-
vidual colonies (~20-50 from one preparation) revealed
high-proliferative potential. These cells were capable of
forming colonies of > 4,000 cells (Figure 1b). After conflu-
ence, cells could be subcultured by splitting them 1:5 -
1:20 and cells proliferated at a high rate. In early passages,
contaminating cells were removed when necessary by a
second CD31 FACS sorting. Cells were stable during cell
culture conditions up to passage 30-40 (Figure 1c, d).
Proliferation of mouse lung EPCs was compared with
endothelioma cells isolated from a cognate mouse strain
over a six-day period. After a two-day lag phase, the num-
ber of EPCs was 3.2-fold higher than that of endothe-
lioma cells on day 4. The significant difference in cell
growth was also present after 6 days (Figure 2). The data
show that normal mouse lung EPCs grow significantly
faster than PmT oncogene-transformed mouse endothe-
lioma cells. Proliferations experiments in the presence of
VEGF-A show, that the growth factor has only a low
effect (~20% at 20 ng/ml VEGF-A) to enhance prolifera-
tion in vitro (data not shown). Although the mechanism
for such a high proliferation rate remains unknown, the
data underline the existence of highly regenerative
endothelial precursor cells in the murine lung.
A key feature of stem cells is their ability to maintain
stem cell properties after division, known as self-renewal.
To exclude the possibility of overestimation due to cell
aggregation or formation of secondary colonies, a single-
cell clonogenic assay was performed by culturing single
cells by limiting dilution in individual wells of 96-well
plates. We found that ~15% (± 3.6%) of the wells con-
tained highly proliferating colonies. These wells were 80-
100% confluent after 18-20 days and had a cell number of
4.3-104 (± 1.4 × 104) cells/well at the end of the experi-
ment (day 28). From the highly proliferating clonal MLM-
VECs six lines were established and maintained in culture
for several passages. Clones were cryopreserved at pas-
sage 15 and 20. From these cultures four clones were fur-
ther characterized for BEC (blood endothelial cell) and
LEC (lymph endothelial cell) markers (see below). TheSchniedermann et al. BMC Cell Biology 2010, 11:50
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abundance of endothelial precursor cells within the
MLMVEC population provides an explanation for the
accelerated growth of MLMVECs as compared with
mouse endothelioma cells.
Mouse lung primary EPCs in early culture are 
heterogeneous and have the potential to differentiate into 
lymphatic and blood endothelial cells
In one of the earliest reports on the isolation of human
BECs and LECs from a dermal cell suspension, it has been
shown that the cells form separate homotypic clusters
[18]. Early after CD31-mediated isolation, our cells
formed colonies as described previously for human ECs,
in which a cluster of LECs is surrounded by BECs (Figure
3; additional file 1). The LECs are positive for the three
key lymphendothelial markers Podoplanin, Lyve1 and
Prox1. BECs, which are more strongly positive for CD31,
are negative for Lyve and Prox1. Occasionally, BECs gen-
erate sprout-like structures in these early cultures (Figure
3). Some cells express low levels of Lyve1 as indicated by
the yellow color. After Lyve1 cell sorting clusters were
predominantly made of LECs (additional file 1). These
observations were made during early passages and we
speculated that at least some of the isolated progenitor
cells have a dual capacity to differentiate into BECs and
LECs in vitro.
To study the hypothesis if a dual differentiation capac-
ity can be found in endothelial precursor cells, a single-
cell clonogenic assay was performed. Four subclones
derived from a single-cell suspension were used to study
the expression of CD31, Lyve1, Podoplanin and Prox1.
The results showed very clearly, that both endothelial cell
types could be found in each subclone, indicating that the
precursor cells are bipotent. A representative result is
shown in Figure 3. Single EPCs from microvascular lung
have the ability to generate lymph and blood vessel
endothelial cells under in vitro conditions.
We also observed that isolated mouse lung endothelial
cells were either Lyve1+ or Lyve1- and that the majority
seems to represent LECs and the minority BECs (addi-
tional file 2). Upon Lyve1 and CD31 cell sorting and fur-
ther culturing for 10 days, a high proportion of the
Figure 1 Cultured mouse lung EPCs at different time points after isolation. Three lungs were used for magneto bead isolation and cells were 
plated in one well of a 12- or 6-well plate. a) One day after cell isolation, the inset in a) shows a small colony with high replication capacity. b) Homo-
geneous large colonies with high proliferation capacity have formed six days after isolation. c) Lung EPCs in passage 12 and d) in passage 31. Scale 
bar = 200 μm.Schniedermann et al. BMC Cell Biology 2010, 11:50
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CD31+/Lyve1- cells were either positive (~71%) or still
negative for Lyve1 (additional file 3), - adjusting to a simi-
l a r  r e l a t i o n s h i p  a s  b e f o r e  ( a d d i t i o n a l  f i l e  2 ) .  T h i s  w a s
again visible after another passage of these cells (~78%
Lyve1+ cells). This may indicate that early isolated EPCs
may have the potential to differentiate into BECs and
LECs. Due to the high proliferative capacity of the pre-
cursor cells, differentiated cells are "diluted" during culti-
vation and a fixed segregation of endothelial cell types
may occur.
Mouse lung EPCs are capable of vascular sprout formation
One of the key characteristics of endothelial cells is the
intrinsic capability to form vascular networks on Matrigel
in vitro. We, therefore, examined the capability of our
lung EPCs at low passage and at high passage and of
immortalized endothelioma cells to form networks on
Matrigel-coated wells. To increase differentiation into
radial sprout-like structures, cells were predifferentiated
overnight as spheroids in hanging drops. Mouse EPCs
generate capillary sprouts as early as 3-5 days after seed-
ing (F igur e 4a). Longer e xposur e of t he c e lls genera t es
extensive network formation and more cells from the
spheroid are involved in vascular sprout formation (Fig-
ure 4b). However, immortalized endotheliomas are also
able to differentiate into vascular sprouts (Figure 4c). The
length of these structures was measured 5 days after plat-
ing and resulted in an average range of 200-250 μm. The
growth factor combination of hepatocyte growth factor
(HGF) and endothelial cell growth factor (ECGF or
endothelial cell growth supplement) had the most promi-
nent effect on sprout length (additional file 4). The data
indicate that mouse EPCs from the lung have the ability
to form vascular networks under in vitro conditions.
Characterization of mouse lung EPC and endothelial 
markers
The use of cell surface markers for the characterization of
cell type specificity has greatly improved the phenotyping
of mouse endothelial cells, because these change their
morphology depending on passage number and rate of
c o n f l u e n c e .  I n  t h i s  s t u d y ,  w e  s o u g h t  t o  d e t e r m i n e
whether mouse EPCs express panendothelial markers as
well as markers for progenitor cells and for BECs and
Figure 2 Mouse lung EPCs show a high proliferation capacity if compared with mouse endothelioma cells derived from the same mouse 
strain. Serum-stimulated growth was compared in equivalently seeded EPCs and endothelioma cells over a 6-day period. After a lag phase, a signifi-
cantly increased growth rate appears in EPCs compared to endothelioma cells.Schniedermann et al. BMC Cell Biology 2010, 11:50
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LECs. The key endothelial marker, besides cobblestone
morphology, is CD31 (PECAM-1). Only cells from colo-
nies were used in this study, which were more than 90%
positive for this marker. Some cells from early passages
were CD31 FACS sorted again if necessary. Routine FACS
analyses between passage 4-8 indicated that more than
99% (99,5 ± 0.2%) of MLMVECs were CD31+. Other
panendothelial markers include CD102 (ICAM-2) and
CD105 (endoglin), which are also expressed in EPCs (Fig-
ure 5). MLMVECs at low passage were positive for
CD144 (~92%) and the four subclones derived from a sin-
gle cells suspension were 54-98% positive for CD144 (not
Figure 3 Heterogeneity of mouse EPCs immediately after isolation and EPC subclones are bipotent. A-B) CD31+ BECs surround LECs, which are 
in the centre of a growing colony and which are Lyve1 positive. BECs are more positive for CD31 than LECs and all LECs specifically express the tran-
scription factor Prox1. C-D) After a single-cell clonogenic assay all cells from two representative subclones (D5 and B3) are positive for CD31, a panen-
dothelial marker. Only cells differentiated into lymph endothelial cells (LECs) are Lyve1 or podoplanin positive. 150-200-fold.
Figure 4 Mouse EPCs from lung exhibit rapid in vitro tube formation in Matrigel. a) Low passage EPCs were examined after seeding on Matrigel-
coated plates after a 5-day period. b) Same as in a) but with high passage EPCs after a 14-day period. c) Mouse endothelioma cells were examined 
after seeding on Matrigel-coated plates after a 5-day period.Schniedermann et al. BMC Cell Biology 2010, 11:50
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shown). For Griffonia simplicifolia lectin, it was shown
that this interacts with murine microvascular endothelial
cells [11], which could also be confirmed in our study
(data not shown). Thus, the isolated mouse lung EPCs
express classical endothelial cell markers and display a
microvascular phenotype. Further, we sought to deter-
mine whether the EPCs express markers for circulating
and resident EPCs as originally shown by Asahara and
colleagues for circulating cells and for resident rat EPC by
Avarez and colleagues [11,19]. Expression of CD34
(mucosialin), VEGFR-2 (KDR), VEGFR-3 (Flt-4), and
CD133 (prominin-1) are widely accepted markers for cir-
culating EPC. Expression of CD34, VEGFR-2 and CD45
(leukocyte common antigen), but not CD133 define a
Figure 5 Mouse lung EPCs retain a microvascular endothelial phenotype. Immunophenotyping of cells was performed with flow cytometric 
analyses. Mouse lung EPCs express the pan-endothelial markers CD31, CD102 and CD105. They also express circulating EPC markers CD34, CD133, 
vascular endothelial growth factor receptors 2 and 3 (VEGFR-2 + VEGFR-3). The new marker LA5 and MECA32/PV1 for blood endothelial cells (BEC) is 
also expressed as well as the lymphatic markers Lyve1 and podoplanin. The pan-lymphocyte marker CD45 was not detectable.Schniedermann et al. BMC Cell Biology 2010, 11:50
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population of resident conduit vessel wall EPCs [11]. Very
similar to circulating and vessel wall-derived EPCs,
mouse lung EPCs express CD34, CD133 and VEGFR-2
(Figure 5). However, cells were negative for CD45, for
CD117 (c-kit or SCF receptor) and CD41, which are
markers for leukocytes and hematopoietic stem cells
(data not shown). As discussed before, our progenitor
cells were also analyzed for specific LEC markers. Expres-
sion of Lyve1, VEGFR-3 and podoplanin indicated that a
least a subpopulation of the cells are committed to lym-
phatic endothelial differentiation (Figure 5). On the other
hand, these cells express LA5 and MECA-32/PV-1, mark-
ers very recently described for mouse blood endothelial
cells [20]. From two isolates we have also made a two
colour labeling using Lyve1 and MECA32/PV-1 or Lyve1/
LA5 (additional file 5).
A very classical marker for vascular endothelial cell is
eNOS or its product NO (nitric oxide). Here we have
used the cell permeable dye DAF-2 (see methods) which
is relatively non-fluorescent. However, in the presence of
NO the derivate is converted to the fluorescent derivate
as show by FACS analysis indicating, that the cells pro-
duce NO (additional file 6).
Mouse EPCs are not transformed
Based on the high proliferation rate and the high vasculo-
genic capacity under culture conditions, we investigated
the possibility that these cells might be transformed and
display a malignant phenotype. Therefore, we determined
anchorage-independent cell growth in a 0.8% agar matrix.
As a control, a mouse beta tumor cell line (βTC) was used
in parallel with the same number of cells per well. Mouse
EPCs did not display proliferative capacity, and no clus-
ters of cells were found throughout the agar (Figure 6).
Also, when EPCs from different isolations and passage
numbers were used, we could not detect cluster forma-
tion or growth on soft agar during a period of 8 days. Beta
cell tumors formed numerous large colonies of more than
1000 cells (Figure 6). These results support the observa-
tion that, although mouse lung EPCs are fast-growing
cells with a capacity for self-renewal, they do not display
any signs of malignancy or transformation.
In vivo vessel formation of mouse EPCs in Matrigel implants
One of the key questions to be answered was whether
mouse EPCs possess the ability to generate capillaries and
larger blood and lymphatic vessels in vivo. This is a criti-
cal issue and should be displayed by any cell type denoted
EPC. Before implantation, we marked cells by lentiviral
transduction in order to express GFP, which allows for
discrimination between endogenous and exogenous
mouse endothelial cells. To facilitate differentiation, EPCs
were cultured overnight as hanging drops, which allows
c e l ls  t o  a d h e r e  t o  ea c h  o t h e r  a n d  t o  s t o p  p r o l i f e r a t i o n
(Figure 7A). Mouse EPCs were then mixed in Matrigel (~
400,000 cells/plug) and injected subcutaneously into the
neck of a normal mouse. Plugs were harvested 10-11 days
after injection. At that time, numerous blood vessels were
found in all plugs that had been seeded with EPCs,
whereas in control plugs without cells but with VEGF and
bFGF, only a small number of blood vessels was present.
Implanted EPCs could be visualized by staining with anti-
GFP antibodies and we observed that cells started to line
up into tube-like structures. Tubes which stained positive
for podoplanin, a reliable marker for lymphatic vessels
could be identified (Figure 7B). Additionally, cells positive
for GFP and LA102, a marker for lymph endothelial cells,
but negative for CD45 could be found in tube-like struc-
tures (additional file 7). Single cells, positive for GFP and
D A P I  b u t  n o t  i n v o l v e d  i n  t u b e  f o r m a t i o n ,  w e r e  e i t h e r
podoplanin-positive or negative (Figure 7B). Additionally,
GFP-transfected EPCs were also found in blood capillar-
ies. Other Matrigel infiltrating cells, which were obvi-
ously immune cells and fibroblasts did not contribute to
tube formation, and were GFP-negative. Triple staining
with anti-GFP, anti-podoplanin and anti-CD31 indicated
that blood and lymphatic networks could exist indepen-
dently in the same implanted Matrigel plug (additional
file 8). A dense network of numerous, perfused vessels
could be seen, positive for CD31 and containing a chime-
ric pattern of GFP-positive and negative vessels (Figure
7C). These vessels obviously contained both endogenous
ECs and implanted EPCs. For de novo vessel formation,
we used EPCs from different isolations and found that all
cells were able to generate vessels that were structurally
similar to the vessels described above. The results illus-
trated that lung endothelial progenitor cells are able to
generated functionally and structurally normal lymphatic
and blood vessels.
Figure 6 Mouse EPCs do not display evidence of transformation. 
The evaluation of anchorage-independent growth was examined in 
mouse EPCs and cells derived from a beta cell tumour seeded onto a 
soft agar matrix. Whereas EPCs did not grow on soft agar, beta tumour 
cells (used as control) formed frequent colonies during the 8 days of 
cultivation. 50-fold.Schniedermann et al. BMC Cell Biology 2010, 11:50
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Discussion
Endothelial precursor cells are found in different niches
Bone marrow as well as peripheral blood of adults and
umbilical cord blood of newborns contain special sub-
types of progenitor cells, which are able to differentiate
into mature endothelial cells. Under conditions of tissue
regeneration or hypoxia they contribute to re-endotheli-
alization of denuded vessels and neo-angiogenesis
[19,21]. These angiogenic cells have properties of angio-
blasts and are termed endothelial progenitor cells (EPCs).
The three main cell surface markers of this cell type are
CD133, CD34 and VEGFR-2/KDR. Within the systemic
circulation, EPCs gradually lose their progenitor proper-
ties and start to express markers for mature endothelial
cells, such as VE-cadherin and eNO synthase [13]. Cul-
tured endothelial cells isolated from human umbilical
vein or aorta contain a small amount of EPCs, which can
be discriminated from mature, differentiated ECs by their
proliferative, colony-forming potential [13]. Recently,
human EPCs have also been characterized and isolated
from the internal thoracic artery by their potential to
form capillary sprouts. These macrovessel-wall derived
EPCs express markers for mature endothelial cells after
tumorigenic activation [22]. Very recently these precur-
sors have been described as endothelial outgrowth cells
(EOCs) and differentiated from EC-like cells and circulat-
ing endothelial cells [16]. Together, the data have led to
the concept that EPCs are a heterogeneous group of pre-
cursor cells, which can be found in different niches, for
instance bone marrow, circulating blood and vascular
wall, participating in both new blood vessel formation
(vasculogenesis) and vascular homeostasis [6,23].
In the present study we sought to determine whether
adult mouse lungs can be used as donor organs for the
isolation of vascular endothelial cells, to be used for in
vitro and in vivo proliferation studies. We found micro-
vascular ECs, which possess an intrinsic ability to prolif-
erate at high rates and differentiate in vitro into lymph
and blood vascular endothelial cells. Subpopulations of
these cells segregate in early passages and form homoge-
neous clusters of BECs and LECs. A similar behaviour has
been reported for cultured human dermal microvascular
endothelial cells [18]. In vivo, predifferentiated microvas-
cular endothelial cells from the mouse lung can undergo
de novo hemangiogenesis and lymphangiogenesis. The
high proliferative capacity of a subpopulation of cells and
the heterogeneity of early isolated cells suggests the pres-
ence of progenitor cells as an essential part of lung vascu-
lar cells. Our findings demonstrated that in contrast to
circulating or resident conduit vessel wall-derived EPCs,
lung EPCs express classical endothelial markers as well as
markers uniquely found in circulating progenitor cells.
They also express markers typical for lymph endothelial
cells and blood endothelial cells but lack the expression of
leukocyte antigens as well as (hematopoietic) stem cell
markers.
During a literature search for similar cells, we found a
very recent report by Alvarez and colleagues, who
describe that rat lung microvessels are enriched with
endothelial progenitor cells (EPCs) [11]. This report
shows that the pulmonary microvascular endothelium
contains different subpopulations of ECs, many of which
Figure 7 In vivo studies of mouse lung EPCs after lentiviral trans-
duction with GFP marker gene. A) Cells as a monolayer (left) or as 
spheroids (right) used for Matrigel implantation into mice. B) De novo 
formation of lymphatic vessels as revealed by double staining with 
anti-GFP and anti-podoplanin (which is LEC-specific) in combination 
with nuclear Dapi staining. Note that the diagonal vessel in the picture 
expresses both markers. C) De novo formation of blood vessels as re-
vealed by double staining with anti-GFP and anti-CD31 (strong CD31 
staining is characteristic for BECs) in combination with nuclear Dapi 
staining. Erythrocytes in the vessels display green/yellow background 
fluorescence.Schniedermann et al. BMC Cell Biology 2010, 11:50
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are EPCs that can be activated to form capillary-like
tubes  in vitro and  in vivo.  T h e y  c a l l e d  t h e m  r e s i d e n t
microvascular endothelial progenitor cells. Because of
the similarity of the early growth characteristics and the
identical organ used for isolation, we assume that we have
isolated the corresponding progenitor cells from mice.
Lung side population (SP) cells are also resident lung pre-
cursor cells with both epithelial and mesenchymal poten-
tial. Neonatal lung SP and subsets of lung SP from
neonatal mice are VEGFR-2/FLK-1+, bind EC specific lec-
tins and form networks in matrigels and therefore dem-
onstrate endothelial potential [24]. Earlier gene
expression profiling studies of lung SP cells from prenatal
mice divided into CD45+ and CD45- cells revealed over-
expression of endothelial genes within the CD45- side
population [25].
Mouse lung EPCs possess hemangiogenic and 
lymphangiogenic potential
Mouse lung EPCs as described in our study are vasculo-
genic in Matrigel assays in vitro and  in vivo. To date,
mouse and rat lungs represent the richest sources of
EPCs, which possess high hemangiogenic and lymp-
hangiogenic capacities [11]. Immunophenotyping has
indicated that the cell isolates are enriched with EPCs
positive for progenitor cell markers. However, the expres-
sion of markers specific for blood and lymph endothelial
cells indicates heterogeneity of the isolates. Whether this
heterogeneity develops during cell culture or exists
already during the early phase of cell isolation was a
major question to be answered. The limiting dilution
assays clearly show that progenitor cells are bipotent and
differentiate into blood and lymphatic endothelial cells in
vitro and form corresponding vessels de novo in normal
mice.
Together with the recent report from Alvarez et al. our
findings supports the premise that the pulmonary micro-
vasculature is a rich endothelial progenitor niche, which
may regenerate blood and lymphatic endothelium to
maintain vascular homeostasis and contribute to tissue
remodelling and repair [11].
A further interesting aspect, which however, could not
be resolved in this study, is the exact localisation of the
EPC niche within the lung. In addition to a putative direct
position in the endothelial monolayer, a localisation in
the vessel wall or in perivascular tissue may be possible.
Moreover, reliable markers to prospectively identify EPCs
in the intact lung are still lacking. The existence of human
EPCs and stem cells that are capable of differentiation
into mature endothelial cells, hematopoietic and local
immune cells has been studied in fragments of the inter-
nal thoracic artery of adults [22]. The niche was identified
between smooth muscle and adventitial layers of the
artery wall. These cells were named vascular wall resident
endothelial progenitor cells (VW-EPC). Although CD45+
cells have been found in the same niche, it has been pos-
tulated that these cells differentiate into macrophages and
hematopoietic cells, but do not participate in capillary
sprout formation [22], which needs to be further investi-
gated.
Angiogenic processes within the postnatal pulmonary
circulation are difficult to study and the phenomenon is
not generally accepted. Angiogenesis may occur within
the lung systemic circulation to repair pulmonary circula-
tion defects and to restore blood flow [11]. Lung tissue is
densely supplied with blood and lymph vessels and both
vessel types possess high plasticity to form new vessels,
for example, during inflammation after pathogen infec-
tion [26]. Based on this observation, we assumed that
genuine precursor cells have the intrinsic capacity to dif-
ferentiate into blood endothelial cells (BECs) and lym-
phatic endothelial cells (LECs), which could be
demonstrated in this study. Vessel formation has been
studied in mouse models for acute or chronic inflamma-
tion of the lung. Bacterial infection of the respiratory
tract is associated with dramatic morphological changes
in the wall of the airways and in the vasculature. Remod-
e l l i n g  o f  b o t h  b l o o d  v e s s e l s  a n d  l y m p h a t i c s  c a n  b e
observed when mice are infected with the bacterium
Mycoplasma pulmonis [26]. Bacterial infection induces
rapid hemangiogenesis and lymphangiogenesis by the
increased expression of vessel specific growth factors
released either by macrophages or other immune cells
and epithelial cells [27]. Inflammation-induced lymp-
hangiogenesis and hemangiogenesis in the lung obviously
prevent oedema formation and facilitate the transport
and traffic of immune cells to combat acute inflamma-
tion, and support respiration [26].
Conclusion
With our results presented here, we finally demonstrate,
that mouse lung EPCs are intrinsically capable of forming
blood and lymph vessels de novo. It will be important to
assess how these cells contribute to normal endothelial
cell turnover and respond to injury. Novel mouse models
are needed to elucidate challenging questions concerning
the direct involvement of lung-derived EPCs in the neo-
formation of blood and lymph vessels and their fate dur-
ing remodelling, repair and inflammation.
Methods
Immortalized Endothelial Cells and Tumor Cells
The generation of endothelioma cell lines (polyoma mid-
dle T-immortalized mouse endothelial cells) from mouse
embryos (Balb/c and C57Bl/6) has been described previ-
ously [17]. As a model for mouse tumor cells we used
pancreatic beta cell tumor (βTC) [28].Schniedermann et al. BMC Cell Biology 2010, 11:50
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Animals
All studies involving the use of mice were approved by
our local institutional animal care committee. The proto-
cols were also approved by the regional council on animal
care and correspond to the requirements of the American
Physiology Society.
Isolation and culture of mouse lung microvascular 
endothelial cells
Mouse lung microvascular endothelial cells (MLMVECs)
were isolated from mouse lungs using a magnetic cell
separation method and cultured as previously described
[29]. Briefly, after euthanasia, three mice were subjected
to thoracotomy and the lungs were rinsed with PBS via
the right cardiac ventricle and excised. After removal of
the larger blood vessels the lungs were minced under
sterile conditions with scissors and placed in a 60-mm
dish containing DMEM. Tissue was digested with colla-
genase A (Cat.no. 10103586001; Roche, Germany), rinsed
with DMEM and the collected cells were strained
through a 40 μm cell strainer (BD Bioscience, Germany).
Cells were incubated with anti-CD31-coated Dynabeads
(rat, clone MEC13.3 BD; Cat.no.110.035, Dynal, Norway)
and separated in a magnetic field. After the washing away
of the unbound cells, the beads were released by trypsin/
EDTA treatment or cells were seeded with the micro-
beads. Cell-culture medium was replaced with DMEM
enriched with 20% FBS (Cat. no. S1810; Biowest, France).
After 8 -10 days, cells were separated again by FACS sort-
ing (FACS Aria, BD Bioscience, Germany) using the same
CD31 antibody as before. Immunophenotyping of CD31+
cells was carried out by flow cytometry after cell expan-
sion (passage 4-6) using a previously described multi-
panel of cell surface and cytoslic markers [17].
Additionally, cells were characterized for markers more
specific for blood or lymph endothelial cells [30]. Pas-
sages 6 -20 were used for consecutive experiments.
Cell growth
MLMVEC cells were seeded at 1 × 104 cells/cm2 in gela-
tinised separate six-well plates or later in small cell cul-
ture flasks (25 cm2). The medium contained DMEM and
15-20% FCS (MBE medium) and has been described pre-
viously [17]. Cells were fed at least twice a week and split
1:4 up to 1:16 after confluence. Growth studies were per-
formed in duplicate or triplicate and for studies with
growth factors, endothelial cell growth supplement
(ECGF, Cat. no. 300-090; Reliatech, Germany) was omit-
ted from the media (ECGF-free cell growth protocol).
Growth was determined by electronic cell counting from
day 0, at 48-h intervals. Results show the average of dupli-
cate/triplicate measurements repeated at least twice.
Proliferation assays
MLMVECs and endothelioma cells were seeded at 1.5 ×
104/well in separate 48 well plates (1,1 cm2/well) in MBE
medium. Following 72 h incubation at 37°C with 5% CO2,
the medium was replaced and this time point was desig-
nated day 3. Proliferation studies were performed in
duplicate. Cell growth was determined after day 3 at 24 h
intervals, using an electronic cell counter (Casy Systems,
Germany). Results denote the average of duplicate mea-
surements repeated at least once. For the proliferation
assay in the presence of growth factors, cells were seeded
in minimal medium (in 5% FCS w/o ECGF) supple-
mented with the growth factors and measured over 4-6
days with one growth factor exchange after three days.
For proliferation assays in the presence of VEGF-A
(mouse VEGF164) we used 5 and 20 ng/ml growth factor.
Limiting dilution analysis
Limiting dilution analysis was performed as described
earlier with some modifications [31]. The single-cell clo-
nogenic assay was performed with MLMVECs from one
isolation at 80-100% confluence. Briefly, cells were
trypsinized, and from the suspension the cell number was
electronically determined (Casy 1 Cell Counter). We
diluted our cells to one cell per 100 μl of standard culture
medium and then dispended 100 μl/well into two and a
half gelatine-coated 96-well plates. Cells were examined
daily under the microscope to study their colony-forming
ability. After one week, wells were supplemented with
another 100 μl of standard culture medium. Cells were
further cultured at 37°C with 5% CO2 and 21% O2 for
another three weeks. After 4 weeks all wells, which con-
tained at least one cell, were counted. Quantification of
moderately and highly proliferating colonies was per-
formed independently by two persons by visual inspec-
tion at x40 magnification. Results denoted the average
from 240 wells. Highly proliferating, clonogenic MLM-
VECs were obtained after further expanding colonies
from confluent wells.
Immunophenotyping by FACS Analysis
MLMVECs and other mouse endothelial cells were
treated with accutase (Cat.no. L11-007, PAA, Austria)
and suspended at 1 × 105 cells per tube in 1 ml micro-
tubes containing 200 μl of cold PBS (calcium and magne-
sium free) supplemented with 2% FCS. For the
immunostaining, cells were incubated for 15 min on ice.
All cells were rinsed with cold PBS/2%FCS and incubated
with the primary antibody or with fluorescein-conjugated
lectin or isotype control antibody for 30 min on ice in the
dark. Cells were rinsed in cold PBS/2% FCS and then
incubated with the corresponding fluorescent dye-conju-Schniedermann et al. BMC Cell Biology 2010, 11:50
http://www.biomedcentral.com/1471-2121/11/50
Page 11 of 13
gated secondary antibody. At the end of antibody incuba-
tion, cells were transferred to flow cytometric tubes
(Micronic, The Netherlands) and subjected to flow analy-
sis using FACS Calibur (Becton Dickinson). We used the
following primary antibodies: CD31 (rat clone MEC13.3;
BD), CD34 (rat clone RAM34; BD), CD45-FITC (rat
clone 104, BD Pharmingen), CD102 (rat clone 3C4(mlC2/
4); BD), CD105 (rat #6J9; Reliatech), CD144 (rat clone
11D4.1; BD), VEGFR-2 (rat clone Avas12α1; BD),
VEGFR-3 (rat Cat. no. 103-M36, Reliatech), Lyve1 (rabbit
Cat. no. 103-PA50AG; Reliatech), podoplanin (hamster
Cat. no. 103-M40; Reliatech), PV1/Meca32 (rat; U.
Deutsch), LA102 (rat Cat.no. 103-M152; Reliatech) and
LA5 (rat, Cat.no. 103-M154; Reliatech). The following
primary antibodies for HSC were used: CD117-PE (rat
120-002-406; Miltenyi Biotech), CD133 (rat clone 13A4;
eBioscience, U.S. and rat clone MB9-3Ga, Miltenyi Bio-
tech, Germany) and CD41-PE (rat clone MWReg30;
eBioscience, US). For lectin binding we used the FITC-
conjugated Griffonia simpliciflolia (Cat. no. FL-1101; Bio-
zol, Germany). For immunodetection of the von Wille-
brand factor, cells were incubated with the primary and
secondary antibodies in the presence of 0.15% TritonX-
100. We used the following conjugated secondary anti-
bodi es:  goa t  an t i ra t -FIT C  (J ac kson IR,  U .S.) ,  g oa t -a n t i
rabbit-FITC (Jackson IR), goat-anti-hamster-PE (Jackson
IR). As a control, cells were incubated with secondary
antibodies exclusively (negative control). Confirmation of
protein expression or lectin interaction in MLMVECs
was the right-shift of the curve as compared with that of a
corresponding control.
Measurement of NO production
The cell-permeable diacetate derivate, DAF-2 DA (4,5-
Diaminofluorescein.diacetate) was used to measure NO
production (Cat. no. ALX-620-056; Alexis, Switzerland).
After loading and subsequent hydrolysis by cytosolic
esterases, DAF-2 is released, which is relatively non-fluo-
rescent at physiological pH. In the presence of NO and
O2, DAF-2 is converted to the fluorescent triazole deri-
vated, DAF-2T [32]. Briefly, EPCs grown in 6-well plates
overnight were than incubated with 5 μM fresh DAF-DA
in 1 ml PBS for 30 min. After washing, cells were
detached and transferred to FACS buffer for FCS analysis
(see above). NIH/3T3 cells have been initially used as
control cells and have been found to be negative for NO.
Matrigel in vitro outgrowth assay
To study sprouting angiogenesis in vitro, mouse endothe-
lium spheroids of a defined cell number were generated
as described previously [33]. Briefly, ECs were suspended
in MBE culture medium containing 0.25% (wt/vol)
methyl cellulose and cultured overnight in hanging drops
of 50 μl. The cells formed single spheroids with a defined
cell number. Matrigel (BMM Matrigel; BD Bioscience,
Germany) was diluted 1:3 with serum-free endothelial
cell medium (Cat. no. U15-002, PAA, Austria), supple-
mented with various growth factors (HGF, ECGF, VEGF-
A, bFGF, VEGF-C, TNF-α) and 150 μl was mixed with
each spheroid and seeded in 48-well plates (as dupli-
cates). Wells were analysed for sprout formation using
phase-contrast microscopy at 1, 5 and 14 days after seed-
ing. The average length of sprouts was measured with a
digitalized Zeiss photomicroscope and compared to the
negative controls. Results denote the average of multiple
measurements of at least two separate experiments.
Green fluorescent protein and luciferase transfection
Lentiviral constructs encoding green fluorescent protein
(GFP; pPREGFPSIN) and luciferase (LUC; pJSCMVLuc)
without antibiotica resistance, were produced as previ-
ously described [34]. Low passage MLMVECs and high
passage MLMVECs (> 20) were seeded in a 12-well plate,
supplemented with standard culture medium and incu-
bated to about 60-70% confluence. The medium was
removed and culture supernatant containing lentiviral
particles constructs, was added to the cells in the pres-
ence of 8 μg/ml Polybrene for 8 h (Sigma). The infected
cells were cultivated as a pool of infected cells. The infec-
tion efficiency varied between 40-60% depending on the
expression cassette and the cell type. For maintenance the
medium was changed twice a week until cells were con-
fluent and used for liquid nitrogen freezing and for in
vivo Matrigel injections.
Matrigel-Mediated de novo Vessel Formation in vivo
MLMVECs were trypsinized, counted and cultured over-
night in hanging drops to allow predifferentiation of cells
in spheroids (~ 10,000 cells/spheroid). Matrigel was sup-
plemented with 500 ng/ml bFGF and VEGF-A and used
with or without spheroids. For each injection, about 30-
50 spheroids were mixed in 300-400 μl unpolymerized
Matrigel at 4°C. The mixed solution was injected subcu-
taneously (left and right dorsal region, two plugs per ani-
mal) into mildly sedated (ketamine 100 mg/kg ip) Balb/c
female mice using a 20-gauge needle. The injected Matri-
gel polymerizes at body temperature and becomes a plug.
As controls, Matrigel was injected on the left side without
cells but with growth factors. 10-12 days after injection,
Matrigel plugs were excised and treated overnight with
methanol/10% DMSO. Plugs were further immersion-
fixed in 4% paraformaldehyde, treated with saccharose
and embedded in frozen section medium (Neg50; Rich-
ard-Allan Scientific, U.S.).
Immunodetection of MLMCECs in vivo
Excised Matrigel plugs embedded in frozen section
medium were used to prepare cryosections of 16-20 μm
thickness. Non-specific binding of antibodies wasSchniedermann et al. BMC Cell Biology 2010, 11:50
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blocked by incubation with 1% bovine serum albumin
(BSA) for 1 h before incubation with primary antibodies.
The following primary antibodies were used for single
and double-staining: Anti-mouse CD31 (rat clone
MEC13.3; BD), anti-mouse CD45 (rat clone 104; BD
Pharmingen) anti-mouse podoplanin (hamster Cat. no.
103-M40; Reliatech), anti-mouse CD105 (rat #6J9; Reliat-
ech), anti-GFP (rabbit Cat. no. ab6556-25, Abcam, U.K.)
and anti-mouse LA102 (rat Cat. no 103-M152).
The sections were incubated with primary antibodies
for 1 h. After rinsing, secondary antibodies were applied
at 1:100 or 1:200 dilution for 1 h. We used goat anti-rat
TRITC-conjugated, (Jackson IR, U.S.), donkey anti-rabbit
Alexa488 (Pierce, Rockford, U.S.), goat anti-hamster
Alexa594, goat anti-rabbit Alexa594 and goat anti-rat
Alexa350-labeled (MoBiTec, Göttingen, Germany). DAPI
reagent (Hoechst Dye) was added to stain nuclei.
After being rinsed, the sections were mounted under
coverslips with Fluoromount-G (Southern Biotechnology,
U.S.). They were studied with a DM500 B epifluorescent
microscope and Axioplan 2 LSM 510 laser-scanning
microscope (Zeiss, Germany).
Anchorage-independent growth on soft agar
MLMVECs and mouse tumour cells (βTC) as positive
control were suspended in MBE medium and seeded at a
density of ~1 × 103 cells/cm2 in 48 well plates coated with
0.8% soft agar in MBE medium. Cells were incubated at
37°C and 5% CO2. After 8-10 days, plates were studied
with phase-contrast microscopy. Efficiency of anchorage-
independent growth was determined by the capacity of
cells to form colonies (> 100 cells) within the agar. Exper-
iments were performed as duplicates and repeated at
least once.
Additional material
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Additional file 1 Heterogeneity and pattern formation of mouse EPCs 
after isolation and CD31 cell sorting shown at lower magnification. a) 
Pattern formation of almost confluent cells after the first CD31 selection 
shown by phase contrast microscopy. b) The same cells as in a). Heteroge-
neity of cells is demonstrated by immunofluorescence several days after 
Lyve1-positive selection. Note CD31-positive BECs surrounding Lyve1-posi-
tive LECs, which express variable amounts of CD31 (yellow). 100-fold.
Additional file 2 Isolation of MLMVECs from mouse lungs by FACS 
sorting. Low passage (passage 3) MLMVECs were sorted by FACS into 
CD31+/Lyve1+ (gate R1) and CD31+/Lyve1- (gate R2) cells for further subcul-
turing and immunophenotyping. The percentage of cells in the different 
regions is indicated (%).
Additional file 3 Subculturing of Lyve1+ and Lyve1- cells after CD31/
Lyve1 cell sorting. Early passage MLMVEC (passage 3) were FACS sorted 
(same cells as in supplementary figure 2) and separately cultured. Ten days 
after sub-culturing (passage 4) cells were studied again by FACS analysis 
with anti-Lyve1 antibodies. The CD31+/Lyve1+ cells indicated a stable high 
Lyve1 expression (a) whereas CD31+/Lyve- cells now expressed Lyve1 at a 
comparably high rate (c). One passage later (passage 5) some CD31+/Lyve+ 
cells were negative for Lyve1 (b) whereas CD31+/Lyve1- cells were getting 
even more positive for Lyve1 (d).
Additional file 4 Sprout formation of MLMVEC spheroids on Matrigel 
in the presence of different growth factor combinations. Quantitative 
sprout formation of MLMVECs (in μm) in the presence of different growth 
factors 5 days after plating together with Matrigel. Growth factor concen-
trations in Matrigel: VEGF-C (500 ng/ml); VEGF-A (50 ng/ml); bFGF (20 ng/
ml); TNF-α (10 ng/ml); HGF (20 ng/ml); ECGF= endothelial cell growth factor 
supplement (50 μg/ml + heparin). Sprouts were measured with an inverted 
stereo microscope (Zeiss) using specific software (AxioVision Rel. 4.5) for the 
determination of sprout lengths. Cells from A were isolated from C57Bl/6 
mice and cells from B were isolated from Balb/c mice. Values= means ± SD.
Additional file 5 Double labelling of lung EPCs with Lyve1, MECA32 
and LA5. Immunophenotyping of cells was performed with cytometric 
analysis. Mouse lung EPCs are double positive for Lyve1 and MECA32. Only 
one part of the Lyve1+ cells are also positive for LA5. Cells from two isola-
tions have an almost an identical pattern of the three markers.
Additional file 6 Mouse lung EPCs have the capacity to produce NO in 
vitro. Fluorescence detection of NO production was done with a practical 
FACS assay with living cells. Membrane-permeable DAF-2 diacetate has 
been used for indirect detection of NO production.
Additional file 7 Extended in vivo studies of mouse lung EPCs after 
lentiviral transduction with GFP marker gene. De novo formation of lym-
phatic vessels as revealed by double staining with anti-GFP and anti-LA102 
(which is LEC-specific) in combination with nuclear Dapi staining. (Upper 4 
figures). Note that staining with anti-CD45 (leukocyte common antigen) 
resulted in the staining of some scattered cells in the interstitium but no 
double staining with LA102 could be observed. (Lower 4 figures) 200-fold.
Additional file 8 In vivo studies of mouse lung EPCs to detect blood 
and lymphatic networks in the implanted Matrigel. Formation of blood 
and lymphatic networks in the same Matrigel by triple staining with anti-
GFP, anti-podoplanin (LEC-specific) and anti-CD31. Note that the merged 
figure contained GFP-tube forming cells which are CD31 and podoplanin 
positive (LEC) and podoplanin negative cells (BEC). 200-fold.Schniedermann et al. BMC Cell Biology 2010, 11:50
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